# Nucleome Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nucleome-therapeutics

- Industry: Biotechnology
- Headquarters: Oxford, UK
- Website: www.nucleome.com
- Total disclosed funding: $42M
- Latest round: Series A (Oct 19, 2022)
- Investors on record: 5

## About

Based in the UK, and founded in 2019, Nucleome Therapeutics Limited operates as a biotech firm. The company was founded by its CEO Danuta Jeziorska, Jim Hughes, and James Davies. In October 2022, Nucleome Therapeutics Limited raised GBP 37.5 million in Series A funding led by M Ventures, Johnson and Johnson Innovation, Pfizer Ventures Investments, British Patient Capital, and Oxford Science Enterprises.

Nucleome Therapeutics develops and offers various precision medicines for patients suffering from lymphocytes and autoimmune-related diseases. The company provides a therapeutics technology platform, which is a 3D genome analysis platform that uses machine learning models to predict disease-related genetic variations.

The company plans to use the funds raised in October 2022 to support the development of its platform and expand its discovery of novel covalent molecules.

## Funding rounds

- Series A, Oct 19, 2022, $42M — Johnson & Johnson Innovation, Pfizer Venture Investments, Oxford Sciences Enterprises, M Ventures, British Patient Capital

## Investors

- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series A
- Oxford Sciences Enterprises (https://capitalatlas.ai/funds/oxford-sciences-enterprises) — Series A
- M Ventures (https://capitalatlas.ai/funds/m-ventures) — Series A
- British Patient Capital — Series A